Company intelligence / Profile preview
Rejuvenate Biomed
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
Overview
Rejuvenate Biomed’s lead candidate RJx‑01—a proprietary oral combination of metformin and galantamine—has completed a successful Phase 1b trial demonstrating safety and improvements in muscle strength/function for disuse-induced atrophy. A Phase 2 double-blind placebo-controlled trial targeting COPD-related sarcopenia will begin enrolling patients in early/mid–2025. The company leverages AI-driven platforms to generate a pipeline of five combination drugs across multiple age-associated indications.
- Therapeutic areas
- OtherPulmonologyMetabolic Disorders
- Modalities
- Small molecules (combination drugs)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Rejuvenate Biomed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rejuvenate Biomed.